Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C7XM
|
|||
| Former ID |
DNCL002472
|
|||
| Drug Name |
P2045
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 1/2 | [1] | |
| Small-cell lung cancer [ICD-11: 2C25.Y] | Phase 1/2 | [1] | ||
| Company |
Bryan Oncor
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H22O2
|
|||
| Canonical SMILES |
CCCCCC1CCC(CC1)C(=O)O
|
|||
| InChI |
1S/C12H22O2/c1-2-3-4-5-10-6-8-11(9-7-10)12(13)14/h10-11H,2-9H2,1H3,(H,13,14)
|
|||
| InChIKey |
RVLAXPQGTRTHEV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 38792-89-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02030184) Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.